Day 1

Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure Treatment

solaci
solaci
394
0

Editorial Comment: Fifty per cent of all HF patients involves Diastolic Heart Failure or HF with conserved ventricular function. This study aimed at evaluating the efficacy and safety of 25mg spironolactone after a year of therapy. Results showed improved diastolic function, induced structural inverse remodelling, reduced neuroendocrine activation and reduced blood pressure (effects on cardiac structure and function remained significant after adjusting for blood pressure changes). Authors concluded that, in addition to safety, this drug is an effective alternative to treat these patients

aldoHF-slides
B. Pieske
2012-08-25

Original title: Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure

Previous article
PARAMOUNT: Promising results of double action drug treatment for patients with heart failure and preserved ejection fraction .
Next article
DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.
solaci
solaci

More articles by this author

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

solaci - 0
 TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization. Read articleMagnus Ohman2012-08-25

DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.

solaci - 0
 DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.  Read articleJames K. Min2012-08-25

PARAMOUNT: Promising results of double action drug treatment for patients with heart failure and preserved ejection fraction .

solaci - 0
Editorial Comment: This Phase II study included 149 patients following these criteria: NYHA II-IV heart failure, +40 yr, LVEF ≥ 45% NT-proBNP> 400 pg/ml....

ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using Cardio Renal Endpoints.

solaci - 0
Editorial Comment: Morbimortality in diabetic patients is still a matter of deep concern in the context of reduced cardiovascular mortality of recent years. Based...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 1

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

 TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization. Read articleMagnus Ohman2012-08-25
solaci -
SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

Dr. Omar Tupayachi - 0
The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

Dr. Omar Tupayachi - 0
As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

Dr. Omar Tupayachi - 0
In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...